Showing 5211-5220 of 5644 results for "".
- Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edemahttps://modernod.com/news/perspective-protocol-v-sheds-light-on-managing-mild-diabetic-macular-edema/2479555/When it comes to the treatment of diabetic macular edema (DME), ophthalmologists have overwhelming evidence to guide their decision-making—but only up to a point. DME consists of three clinical subcategories: center-involved DME (CI-DME) with visual acuity (VA) impairment, CI-DME with good
- US Outlines Plans to Allow Importation of Certain Prescription Drugs From Canada, Other Countrieshttps://modernod.com/news/us-outlines-plans-to-allow-importation-of-certain-prescription-drugs-from-canada-other-countries/2479556/The US Department of Health and Human Services (HHS) on Wednesday outlined details of two potential pathways that will allow the importation of certain prescription medicines originally intended for foreign markets. The announcement comes the day after HHS Secretary Alex Azar confirmed that Presi
- Acuity Eyecare Group Enters Texas Market With Multiple Acquisitionshttps://modernod.com/news/acuity-eyecare-group-enters-texas-market-with-multiple-acquisitions/2476785/Riata Capital Group announced that its portfolio company Acuity Eyecare Group, an owner and operator of North American eyecare groups and optometry practices, has acquired 11 regional eyecare practices in Texas. These acquisitions are the first for Acuity Eyecare
- CMS Issues Proposed 2020 ASC Payment Rulehttps://modernod.com/news/cms-issues-proposed-2020-asc-payment-rule/2479563/On July 29, the Centers for Medicare and Medicaid Services (CMS) issued its proposed CY 2020 payment rate regulation for hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs). The proposed regulation will soon be published in the Federal Register. The Outpatient Ophthalmic
- Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpointshttps://modernod.com/news/alkahest-phase-2a-study-akst4290-202-in-refractory-wet-amd-meets-primary-and-secondary-endpoints/2476778/Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 w
- European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10https://modernod.com/news/european-medicines-agency-grants-prime-access-to-proqrs-sepofarsen-for-lebers-congenital-amaurosis-10/2476779/ProQR Therapeutics announced that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the Priority Medicines (PRIME) program by the European Med
- Okayama University Research: Prosthetics for Retinal Stimulationhttps://modernod.com/news/okayama-university-research-prosthetics-for-retinal-stimulation/2476774/In a study recently published in Advanced Biomedical Engineering, researchers at Okayama University in Japan report a thin photoelectric film which can stimulate degenerated retinal tissues of the eye. Using electric signals to stimulate tissues is the basis of several medical devic
- MicroSurgical Technology Releases MST 19-Gauge Ahmed Micro Stent Cutterhttps://modernod.com/news/microsurgical-technology-releases-mst-19-gauge-ahmed-micro-stent-cutter/2476768/To address challenging microstent revision surgery, MicroSurgical Technology (MST), in collaboration with glaucoma and cataract surgeon Ike Ahmed, MD, has developed the MST 19-gauge Ahmed Micro Stent Cutter. Bringing precision and control, the new instrument enables an efficient and minimally inv
- Omeros’ Omidria Receives Product-Specific J-Code from CMShttps://modernod.com/news/omeros-omidria-receives-product-specific-j-code-from-cms/2476766/Omeros announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3%. Omidria is
- Allegro Ophthalmics to Present Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at ASRShttps://modernod.com/news/allegro-ophthalmics-to-present-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-asrs/2476765/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD) will be presented during the Americ